Search clinical trials for: 4-Hydroxyphenylpyruvate Dioxygenase

Total 29 results

University of Florida

Completed

Prevention of Dichloroacetate Toxicity

Chronic Disease | Acidosis, Lactic

United States
Theodore S. Johnson
Augusta University

Recruiting

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Glioblastoma | Ependymoma | Medulloblastoma | Primary Brain Tumor

United States
Liverpool University Hospitals NHS Foundation Trust

Recruiting

Questionnaire Follow=up Study Sonia 2 (QSonia)

Alkaptonuria | Homogentisic Acid | Homogentisate Dioxygenase | Alkaptonuria Severity Score Index

United Kingdom
Theodore S. Johnson
National Cancer Institute (NCI); Emory University; Augusta University

Recruiting

Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

Glioblastoma | Ependymoma | Medulloblastoma | Diffuse Intrinsic Pontine Glioma

United States
Washington University School of Medicine
National Cancer Institute (NCI); Incyte Corporation

Recruiting

Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

Rectal Cancer

United States
Tampere University Hospital

Completed

Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)

CLL

Finland
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Renal Cell Carcinoma (RCC)

Canada, France, United States, Spain, United Kingdom, Italy, Taiwan, Australia, Norway, Korea, Republic of, Germany, Russian Federation, Japan, Brazil, Turkey, Ukraine, Hungary, New Zealand, Chile, Ireland
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Head and Neck Cancer

Canada, Spain, Korea, Republic of, United States, Austria, Japan, United Kingdom, Taiwan, Italy, Hungary, Australia, Turkey, Poland, Portugal
Thomas Jefferson University
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Larynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | Pharynx

United States
Edward Kim
Bristol-Myers Squibb; National Cancer Institute (NCI)

Terminated

BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma

United States
Luke, Jason, MD
Lumos Pharma

Withdrawn

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

Advanced Solid Tumors
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

Lung Cancer

United States, Hungary, Spain, Ireland, Italy, Taiwan, Korea, Republic of, United Kingdom, Turkey, Canada, Israel, Australia, Mexico, Russian Federation
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Lung Cancer

Spain, Ireland, Canada, Denmark, Japan, Israel, Korea, Republic of, Malaysia, United States, Turkey, Italy, Ukraine, Switzerland, Russian Federation, Poland, Australia, Estonia, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
NewLink Genetics Corporation

Completed

NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Solid Tumor

United States
Incyte Corporation

Terminated

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

Solid Tumors

United States
Incyte Corporation
Bristol-Myers Squibb

Withdrawn

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Head and Neck Cancer
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Shanghai De Novo Pharmatech Co., Ltd.

Unknown

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

Advanced Solid Tumors

China
Incyte Corporation
Bristol-Myers Squibb

Terminated

Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer

Lung Cancer

United States
Inge Marie Svane
Copenhagen University Hospital at Herlev

Terminated

Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

Malignant Melanoma

Denmark
Genentech, Inc.

Completed

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Solid Tumor

United States
ZhangTao

Unknown

The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure

Repeated Implantation Failure

China
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation

Completed

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes

United States
Inge Marie Svane

Completed

IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients. (IDOvaccine)

NSCLC | Lung Cancer

Denmark
M.D. Anderson Cancer Center
Biogen

Completed

Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma

Lymphoma

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Stage IV Ovarian Epithelial Cancer | Recurrent Ovarian Epithelial Cancer | Recurrent Primary Peritoneal Cavity Cancer | Stage IV Primary Peritoneal Cavity Cancer | Recurrent Fallopian Tube Cancer | Stage IIA Fallopian Tube Cancer | Stage IIB Fallopian Tube Cancer | Stage IIC Fallopian Tube Cancer | Stage... and other conditions
Mahidol University
University of Texas; University of Wuerzburg

Completed

Study of Indoleamine 2,3-dioxygenase Activity, Serum Levels of Cytokines, BDNF, BH4 and Mirtazapine Efficacy in Fibromyalgia Syndrome

Fibromyalgia Syndrome

Thailand

Search clinical trials for: 4-Hydroxyphenylpyruvate Dioxygenase

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations